BPMX - BioPharmX Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
1/30/2019
1/30/2018
1/30/2017
1/30/2016
Total Revenue
15
57
73
100
64
Cost of Revenue
63
83
250
516
237
Gross Profit
-48
-26
-177
-416
-173
Operating Expenses
Research Development
7,596
9,079
9,140
10,158
5,702
Selling General and Administrative
6,332
7,401
7,559
7,852
9,283
Total Operating Expenses
13,928
16,480
16,699
18,010
14,985
Operating Income or Loss
-13,976
-16,506
-16,876
-18,426
-15,158
Interest Expense
-
-
-
-
0
Total Other Income/Expenses Net
-737
-750
238
22
-436
Income Before Tax
-14,713
-17,256
-16,638
-18,404
-15,594
Income Tax Expense
2
2
2
2
4
Income from Continuing Operations
-14,715
-17,258
-16,640
-18,406
-15,598
Net Income
-14,715
-17,258
-16,640
-18,406
-15,598
Net Income available to common shareholders
-14,715
-17,258
-16,640
-18,532
-16,001
Reported EPS
Basic
-
-2.25
-4.75
-13.00
-22.25
Diluted
-
-2.25
-4.75
-13.00
-22.25
Weighted average shares outstanding
Basic
-
7,727
3,436
1,432
718
Diluted
-
7,727
3,436
1,432
718
EBITDA
-
-16,444
-16,824
-18,166
-15,072